(Q38164686)

30 August 2017

title

Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. (English)

1 reference

30 August 2017

1 reference

1 reference

1 reference

Kira Harris

1

1 reference

30 August 2017

Lisa Smith

series ordinal

2

1 reference

30 August 2017

language of work or name

English

0 references

publication date

1 October 2013

1 reference

Annals of Pharmacotherapy

30 August 2017

published in

1 reference

30 August 2017

volume

47

1 reference

30 August 2017

issue

10

1 reference

30 August 2017

page(s)

1348-1352

1 reference

Standards of medical care in diabetes--2013

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1060028013503108

AACE comprehensive diabetes management algorithm 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013503108

Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013503108

Insulin resistance: a metabolic pathway to chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013503108

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013503108

Impact of insulin-sensitizing agents on risk for liver cancer and liver-related death in diabetic patients with compensated hepatitis C cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013503108

Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013503108

The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013503108

Clarifying metformin's role and risks in liver dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013503108

Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013503108

Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013503108

Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013503108

Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013503108

Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013503108

21 January 2018

Identifiers

DOI

10.1177/1060028013503108

1 reference

30 August 2017

1 reference